Catherine Harrington, NP
Pediatrics · Max Meadows, VANPI 1962445627
Payments from drug & device makers
Across 162 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$617
- Novo Nordisk$346
- AstraZeneca$253
- Pfizer$168
- Vanda Pharmaceuticals Inc.$150
- Lilly USA, LLC$135
- plus $761 from 19 others
What the payments were for
- Food & beverage$2,431100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $617 |
| Novo Nordisk | 23 | $346 |
| AstraZeneca | 15 | $253 |
| Pfizer | 11 | $168 |
| Vanda Pharmaceuticals Inc. | 8 | $150 |
| Lilly USA, LLC | 6 | $135 |
| Amgen(2 entities) | 7 | $108 |
| Otsuka America Pharmaceutical, Inc. | 5 | $87 |
| Merck | 4 | $73 |
| Corium, LLC | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Dexcom, Inc. | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Convatec Inc. | 1 | $32 |
| Cranial Technologies, Inc | 2 | $28 |
| Abbott | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Neurelis, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
| GSK | 1 | $17 |
| Alkermes, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $12 |
How this compares
$2,431 in reported general payments places this provider in the 95th percentile of 1,542 pediatrics providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $102,630 |
| TrulicityDulaglutide | 47 | $64,978 |
| FarxigaDapagliflozin Propanediol | 61 | $59,703 |
| MounjaroTirzepatide | 49 | $51,707 |
| EliquisApixaban | 17 | $28,164 |
| JanuviaSitagliptin Phosphate | 19 | $23,488 |
| LinzessLinaclotide | 22 | $19,259 |
| XareltoRivaroxaban | 18 | $17,726 |
| JardianceEmpagliflozin | 13 | $16,074 |
| UbrelvyUbrogepant | 16 | $15,544 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $12,081 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,161 |
| Emgality PenGalcanezumab-Gnlm | 11 | $8,001 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $5,843 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 15 | $3,692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $135 | $116,68596 claims |
| Novo NordiskOzempic, Novolog | $346 | $103,946114 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $253 | $68,86475 claims |
| AbbVieLinzess, Ubrelvy, Synthroid | $617 | $35,51254 claims |
| PfizerEliquis | $168 | $28,16417 claims |
| MerckJanuvia | $73 | $23,48819 claims |
| GSKTrelegy Ellipta | $17 | $12,08112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,542 pediatrics providers in Virginia.
Other pediatrics in Max Meadows
- Fredric GarnerBurke$10.4M
- Ozlem Goker-AlpanFairfax$8.6M
- Richard BennettRichmond$7.3M
- Paul WismanCharlottesville$5.6M
- Sofia TeferiRichmond$3.3M
- Christina UlenVienna$2.4M
- Patricia MulreanyMidlothian$1.5M
- Dominick PastoreRichmond$1.2M
- Christina PeroutkaCharlottesville$1.1M
- William ReesBurke$884K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.